133625-87-3Relevant articles and documents
A simplified route to the (R)-Garner aldehyde and (S)-vinyl glycinol
Campbell, Andrew D.,Raynham, Tony M.,Taylor, Richard J. K.
, p. 1707 - 1709 (1998)
An improved procedure for the conversion of D-serine into tert-butyl (R)-4-formyl-2,2-dimethyloxazolidine-3-carboxylate [the (R)-Garner aldehyde] is described which can be carried out in four operationally simple steps in 88% overall yield. Elaboration of this aldehyde to vinyl glycinol is also described.
Efficient conversion of (S)-methionine into (R)-garner aldehyde
Ravi Kumar, Jalluri S.,Datta, Apurba
, p. 6779 - 6780 (1997)
An efficient method has been developed for the conversion of L-methionine into N,O-protected D-serinal (Garner aldehyde) in good overall yield.
MACROCYCLIC LRRK2 KINASE INHIBITORS
-
Page/Page column 171, (2016/04/09)
The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR
-
Page/Page column 37, (2015/11/03)
This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.